X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $11.25.
Several brokerages recently weighed in on XFOR. Wells Fargo & Company initiated coverage on X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price objective for the company. Weiss Ratings downgraded X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Finally, Leerink Partners started coverage on X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 target price for the company.
View Our Latest Stock Report on XFOR
X4 Pharmaceuticals Stock Up 2.3%
X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. The company had revenue of $8.81 million during the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. On average, equities research analysts anticipate that X4 Pharmaceuticals will post -0.67 EPS for the current fiscal year.
Insider Activity at X4 Pharmaceuticals
In other X4 Pharmaceuticals news, Chairman Adam R. Craig sold 47,436 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total transaction of $210,615.84. Following the completion of the sale, the chairman owned 328,651 shares in the company, valued at $1,459,210.44. The trade was a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President John Volpone sold 24,576 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $109,117.44. Following the sale, the president directly owned 265,305 shares in the company, valued at $1,177,954.20. This trade represents a 8.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 80,555 shares of company stock valued at $356,126. Corporate insiders own 1.13% of the company’s stock.
Institutional Investors Weigh In On X4 Pharmaceuticals
A number of institutional investors have recently modified their holdings of the business. Pettinga Financial Advisors LLC bought a new position in X4 Pharmaceuticals in the second quarter worth about $47,000. SummitTX Capital L.P. bought a new position in shares of X4 Pharmaceuticals during the first quarter valued at approximately $46,000. WINTON GROUP Ltd grew its holdings in shares of X4 Pharmaceuticals by 35.8% during the second quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock valued at $67,000 after purchasing an additional 3,800 shares during the last quarter. AXQ Capital LP acquired a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth approximately $107,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth approximately $104,000. Institutional investors own 72.03% of the company’s stock.
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc (NASDAQ:XFOR) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by abnormalities in the immune system. The company’s research is centered on the CXCR4 pathway, which helps regulate the movement and distribution of immune cells in the body.
X4’s lead product, XOLREMDI (mavorixafor), is an orally administered CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for patients aged 12 and older with WHIM syndrome.
Featured Stories
- Five stocks we like better than X4 Pharmaceuticals
- Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing
- Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
- These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
- Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
